Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Filipits, M; Pirker, R; Dunant, A; Lantuejoul, S; Schmid, K; Huynh, A; Haddad, V; André, F; Stahel, R; Pignon, JP; Soria, JC; Popper, HH; Le Chevalier, T; Brambilla, E.
Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
J Clin Oncol. 2007; 25(19): 2735-2740. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Autor/innen der Med Uni Graz:
Popper Helmuth
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
PURPOSE: The International Adjuvant Lung Cancer Trial (IALT) demonstrated that adjuvant cisplatin-based chemotherapy improves the survival of patients with completely resected non-small-cell lung cancer (NSCLC). The purpose of our study was to determine whether cell cycle regulators are of prognostic and/or predictive value in patients who were enrolled onto the IALT. PATIENTS AND METHODS: Expression of p27Kip1, p16INK4A, cyclin D1, cyclin D3, cyclin E, and Ki-67 was immunohistochemically assessed in tumor specimens obtained from 778 IALT patients. Prognostic and predictive analyses were based on Cox models adjusted for clinical and pathologic parameters. RESULTS: There was a relationship between p27Kip1 status and benefit of cisplatin-based chemotherapy (test for interaction, P = .02). Among patients with p27Kip1-negative tumors, cisplatin-based chemotherapy resulted in longer overall survival compared with controls (adjusted hazard ratio [HR] for death = 0.66; 95% CI, 0.50 to 0.88; P = .006). In patients with p27Kip1-positive tumors, overall survival was not different between patients treated with cisplatin-based chemotherapy and controls (adjusted HR for death = 1.09; 95% CI, 0.82 to 1.45; P = .54). The other cell cycle regulators and Ki-67 did not predict benefit of adjuvant cisplatin-based chemotherapy. None of these biomarkers was significantly associated with overall survival of the patients in the total study population. CONCLUSION: NSCLC patients with p27Kip1-negative tumors benefit from adjuvant cisplatin-based chemotherapy after complete tumor resection. Before establishing p27Kip1 as a routine marker for selection of patients for adjuvant chemotherapy, the predictive value of p27Kip1 has to be confirmed in patients from other trials.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Cell Cycle - drug therapy
Chemotherapy, Adjuvant - drug therapy
Cisplatin - therapeutic use
Female - therapeutic use
Gene Expression Regulation, Neoplastic - therapeutic use
Humans - therapeutic use
Intracellular Signaling Peptides and Proteins - metabolism
Lung Neoplasms - drug therapy
Male - drug therapy
Middle Aged - drug therapy
Prognosis - drug therapy
Treatment Outcome - drug therapy

© Meduni Graz Impressum